Skip to main content
. 2020 Oct 29;13:11125–11137. doi: 10.2147/OTT.S273108

Figure 2.

Figure 2

The expression of SQSTM1/p62 is reduced in MYCN-amplified neuroblastomas. (A) Relative expression of MYCN, SQSTM1, ATG5, BECLIN1, ATG7 and LC3B in 493 primary neuroblastoma tumors, non-amp: MYCN-nonamplified tumors (n=401); amp: MYCN-amplified tumors (n=92). (B) Correlation between mRNA levels of MCT1 and representative autophagy targets in MYCN-amplified neuroblastoma tumors. (C) Representative N-Myc, MCT1 and SQSTM1/p62 immunochemical staining in primary neuroblastoma tumors; sample No.1 and No.2: MYCN-amplified, high stage; sample No.3: MYCN-nonamplified, low stage. The scale bar represents 50μm. (D) The protein expression of LC3-II/LC3-I and SQSTM1/p62 in NB cells treated with 3-BrPA of different concentration by WB analysis.